RNA modifying enzymes

Soft tissue sarcoma
#Clinical trial #RNA modifying enzymes #Sarcoma

Enzyme inhibitor shows early evidence of treating sarcoma 

An RNA-modifying enzyme inhibitor has shown positive results in treating sarcoma patients during a Phase I trial.  STC-15, developed by STORM Therapeutics, demonstrated a disease control rate of 54% at 12 weeks and a median progression-free survival of six months. The trial enrolled 42 patients with advanced… Read More

#Cancer Research #News

Cancer immunotherapy
#Cancer immunotherapy #Cancer research #Clinical trials #Immunotherapy #RNA #RNA modifying enzymes #Storm Therapeutics

Could RNA modifying enzymes boost response rates? 

Cancer immunotherapy has set new standards in cancer care, but many patients are still not responding. RNA modifying enzymes (RME) research could be a way to improve results. DDW’s Megan Thomas reflects on STORM Therapeutics’ approach for the future of this mechanism of action.   Turning points and catalysts… Read More

#Cancer Research #Exclusive Content #Opinion